Ruxolitinib inhibits cytokine production by human lung macrophages without impairing phagocytic ability

Background: The Janus kinase (JAK) 1/2 inhibitor ruxolitinib has been approved in an indication of myelofibrosis and is a candidate for the treatment of a number of inflammatory or autoimmune diseases. We assessed the effects of ruxolitinib on lipopolysaccharide (LPS)- and poly (I:C)-induced cytokin...

Cijeli opis

Bibliografski detalji

Glavni autori:	Nikola Mantov, Mathilde Zrounba, Marion Brollo, S Grassin-Delyle, Matthieu Glorion, Mélanie David, Emmanuel Naline, Philippe Devillier, Hélène Salvator
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2022-08-01
Serija:	Frontiers in Pharmacology
Teme:	ruxolitinib human macrophages Janus kinase (2)-signal transducers and activators of transcription [JAK2-STAT5] cytokine budenoside
Online pristup:	https://www.frontiersin.org/articles/10.3389/fphar.2022.896167/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!